Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Urological/Gynecological Diseases
Vol. 5, Issue 2, 2018
January 09, 2018 EDT
Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain
Carlos Crespo
,
Pedro Blasco
,
Marcelo Guigini
,
Jordi Galván
,
oral muscarinic antagonists
mirabegron
persistence
cost–effectiveness
oxybutynin transdermal patch
idiopathic overactive bladder
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9811
JHEOR
1.
Crespo C, Blasco P, Guigini M, Galván J. Clinical and Economic Evaluation of Transdermal Oxybutynin in the Treatment of Overactive Bladder in Spain.
JHEOR
. 2018;5(2):194-205.
doi:10.36469/9811
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats